# PASO-DOBLE Trial: Dovato vs Biktarvy Head-to-Head Comparison

**ID:** TRT-009
**Year:** 2024
**Journal:** AIDS 2024 Conference (Oral Abstract OAB3606LB)
**Sponsor:** ViiV Healthcare, GeSIDA
**Trial ID:** GeSIDA 11720

---

## Abstract

PASO-DOBLE is the largest head-to-head randomized phase IV trial comparing the 2-drug regimen Dovato (dolutegravir/lamivudine) with the 3-drug regimen Biktarvy (bictegravir/emtricitabine/tenofovir alafenamide) in virologically suppressed people with HIV. Results demonstrated non-inferior efficacy at 48 and 96 weeks, with Dovato showing significantly less weight gain and fewer drug-related adverse events.

---

## Key Concepts

- **Dovato (DTG/3TC)**: 2-drug INSTI + NRTI regimen
- **Biktarvy (BIC/FTC/TAF)**: 3-drug INSTI + dual NRTI regimen
- **Switch Study**: Virologically suppressed patients switched regimens
- **Non-Inferiority**: Primary statistical design

---

## Trial Design

### Study Parameters
| Parameter | Details |
|:----------|:--------|
| Design | Phase IV, randomized, open-label |
| Sites | 30 sites across Spain |
| Network | GeSIDA (Grupo de Estudio del SIDA) |
| Sponsor | ViiV Healthcare |
| Duration | 96 weeks |

### Population
| Criterion | Requirement |
|:----------|:------------|
| HIV status | Virologically suppressed |
| Prior ART | On stable regimen |
| Viral load | <50 copies/mL |
| Randomization | 1:1 |

### Treatment Arms
| Arm | Regimen | N |
|:----|:--------|:--|
| Dovato | DTG 50mg + 3TC 300mg QD | 277 |
| Biktarvy | BIC 50mg + FTC 200mg + TAF 25mg QD | 276 |

---

## Primary Endpoint Results

### 48-Week Efficacy
| Outcome | Dovato | Biktarvy | Difference |
|:--------|:-------|:---------|:-----------|
| Viral suppression (<50 copies/mL) | Non-inferior | Reference | Met endpoint |
| Virologic failure | 0 | 1 | - |

### 96-Week Efficacy
| Outcome | Dovato | Biktarvy | Significance |
|:--------|:-------|:---------|:-------------|
| Maintained viral suppression | **Yes** | Yes | Non-inferior |
| Virologic failures | **0** | 3 | Favorable for Dovato |
| Resistance emergence | **None** | None | Equal |

> "At 96 weeks, Dovato demonstrated non-inferior efficacy in maintaining viral suppression compared with BIC/FTC/TAF, meeting the study's primary endpoint."

---

## Weight Gain Analysis

### Key Finding
| Metric | Dovato | Biktarvy | Difference |
|:-------|:-------|:---------|:-----------|
| Mean weight gain (96 weeks) | **0.84 kg** | 2.35 kg | **1.52 kg less** |
| >5% weight gain | **20%** | 29.9% | Significant |

> "Dovato was associated with a significantly lower mean weight gain (0.84 kg) compared with BIC/FTC/TAF (2.35 kg) through week 96—a difference of 1.52 kg."

### Clinical Significance
| Impact | Relevance |
|:-------|:----------|
| Metabolic health | Lower cardiometabolic risk |
| Patient preference | Important for long-term adherence |
| Body image | Quality of life factor |

---

## Safety and Tolerability

### Adverse Events
| Category | Dovato | Biktarvy |
|:---------|:-------|:---------|
| Drug-related AEs | **7.6%** | 13.4% |
| Serious AEs | Similar | Similar |
| Discontinuations due to AEs | Low | Low |

### Regimen Differences
| Feature | 2-Drug (Dovato) | 3-Drug (Biktarvy) |
|:--------|:----------------|:------------------|
| Drug exposure | Less cumulative | Standard |
| Drug interactions | Fewer potential | Standard |
| Long-term toxicity | Theoretically lower | Standard |

---

## Clinical Implications

### Regimen Selection Considerations
| Factor | Favors Dovato | Favors Biktarvy |
|:-------|:--------------|:----------------|
| Weight concerns | ✓ | - |
| Fewer drugs preferred | ✓ | - |
| HBV coinfection | - | ✓ (contains TAF) |
| Renal concerns | Variable | Variable |

### 2-Drug Regimen Validation
| Finding | Significance |
|:--------|:-------------|
| Non-inferior efficacy | Validates 2-drug strategy |
| Zero virologic failures | Strong durability |
| Less weight gain | Metabolic advantage |
| Fewer drug-related AEs | Better tolerability |

---

## Drug Component Comparison

### Active Ingredients
| Component | Dovato | Biktarvy |
|:----------|:-------|:---------|
| INSTI | Dolutegravir 50mg | Bictegravir 50mg |
| NRTI 1 | Lamivudine 300mg | Emtricitabine 200mg |
| NRTI 2 | - | Tenofovir alafenamide 25mg |

### Resistance Barrier
| Regimen | Barrier | Evidence |
|:--------|:--------|:---------|
| Dovato | High | Zero failures in PASO-DOBLE |
| Biktarvy | High | 3 failures, no resistance |

---

## Conference Presentation

### AIDS 2024
| Detail | Information |
|:-------|:------------|
| Conference | 25th International AIDS Conference |
| Location | Munich, Germany |
| Date | July 22-26, 2024 |
| Abstract | OAB3606LB (Late-breaker) |

> "ViiV Healthcare announces positive data demonstrating 2-drug regimen Dovato is as effective as 3-drug regimen Biktarvy for maintenance therapy of HIV-1."

---

## Expert Commentary

> "Switching to DTG/3TC in virologically suppressed adults living with HIV demonstrated non-inferior efficacy in maintaining viral suppression compared with switching to BIC/FTC/TAF."

### Key Takeaways
1. **2-drug regimens validated** for maintenance therapy
2. **Weight advantage** for Dovato clinically meaningful
3. **No resistance emergence** in either arm
4. **Patient choice** supported by comparable efficacy

---

## Relevance to Project

PASO-DOBLE trial data informs the Ternary VAE project:
- **Drug target sequences**: INSTI binding sites (IN)
- **Resistance barriers**: Sequence constraints on escape
- **Fitness landscapes**: High-barrier drug targets
- **Regimen optimization**: Sequence-based treatment selection

---

*Added: 2025-12-24*
